We show that NOXA deletion, but not BIM deletion, in BCL2 and BCL‐XL‐dependent DLBCL cells both in vitro and in vivo resulted in a highly significant enhanced resistance to both BCL2i and BCL‐XL inhibitors. The gene discussed is BCL2L1; the disease is diffuse large B-cell lymphoma.